Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Pyridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL6515981 | 0.97 | TSHR (0.60) | TSHRNAPRTTDP1ALDH1A1GAA | |
| Pyridine SCHEMBL3908730 | 0.94 | TSHR (0.64) | TSHRNAPRTTDP1ALDH1A1GAA | |
| Pyridine SCHEMBL28351603 | 0.85 | TSHR (0.53) | TSHRNAPRTTDP1GAA | |
| Pyridine SCHEMBL11341725 | 0.84 | NAPRT (0.60) | TSHRNAPRTTDP1SLC6A2SLC6A4 | |
| Pyridine SCHEMBL11002811 | 0.84 | NAPRT (0.60) | TSHRNAPRTTDP1SLC6A2SLC6A4 | |
| Pyridine SCHEMBL6396742 | 0.83 | TSHR (0.69) | TSHRNAPRTTDP1SLC6A2SLC6A4 | |
| Pyridine SCHEMBL1333318 | 0.83 | TSHR (0.69) | TSHRNAPRTTDP1SLC6A2SLC6A4 | |
| 1,1,2,2-Tetrachloroethane SCHEMBL11881109 | 0.80 | TDP1 (0.64) | TSHRNAPRTTDP1SLC6A2SLC6A4 | |
| Pyridine SCHEMBL8061420 | 0.80 | TSHR (0.64) | TSHRNAPRTTDP1SLC6A2SLC6A4 | |
| Pyridine SCHEMBL547127 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461360-B2 | Process for producing γ -mangostin | LAILA NUTRACEUTICALS (US) | 2013-06-11 | — | — | US | disclosed |
| US-20100292490-A1 | A PROCESS FOR PRODUCING GAMMA MANGOSTIN | LAILA NUTRACEUTICALS (IN) | 2010-11-18 | — | — | US | disclosed |
| WO-2009093259-A2 | A PROCESS FOR PRODUCING γ-MANGOSTIN | GOKARAJU GANGA RAJU (IN) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292490-A1 | A PROCESS FOR PRODUCING GAMMA MANGOSTIN | SOST, CYP51A1, GNMT | SLC6A2 4807/4885SLC6A3 4769/4885TSHR 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.